Synthetic lethal targeting of DNA double‐strand break repair deficient cells by human apurinic/apyrimidinic endonuclease inhibitors
Rebeka Sultana(University of Nottingham), Srinivasan Madhusudan(Nottingham University Hospitals NHS Trust), Claire Seedhouse(University of Nottingham), Peter M. Fischer(University of Nottingham), Haitham M.H. Qutob(King Abdulaziz University), Poulam M. Patel(Nottingham University Hospitals NHS Trust), Daniel R. McNeill(National Institute on Aging), Charles A. Laughton, Rachel Abbotts(University of Nottingham), David M. Wilson(Hasselt University), Mohammed Z. Mohammed(University of Nottingham), Małgorzata Z. Zdzienicka(Nicolaus Copernicus University)
Cited by 94
Related Papers
Cisplatin plus Gemcitabine versus Gemcitabine for Biliary Tract Cancer
|New England Journal of Medicine|2010|4.5k
Hallmarks of neurodegenerative diseases
|Cell|2023|1.6k
Docetaxel versus active symptom control for refractory oesophagogastric adenocarcinoma (COUGAR-02): an open-label, phase 3 randomised controlled trial
|The Lancet Oncology|2013|605
Workgroup Report: Public Health Strategies for Reducing Aflatoxin Exposure in Developing Countries
|Environmental Health Perspectives|2006|537